![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1410099
¼¼°è ¼Òµ¶ ĸ ½ÃÀå ¿¹Ãø(2023-2028³â)Disinfection Cap Market - Forecasts from 2023 to 2028 |
¼Òµ¶ ĸ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È CAGR 8.03%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¼Òµ¶ ĸÀº ÀÇ·á±â±â¿Í °ü·ÃµÈ Áúº´ÀÇ ¹ß»ý·üÀ» ³·Ãß±â À§ÇØ ¹Ì»ý¹° ¿À¿°¿¡ ´ëÇÑ ¹æ¾îÀÇ Ãß°¡ ÃþÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. ÇコÄÉ¾î °ü·Ã °¨¿°À̳ª ¾Ï ȯÀÚ Áõ°¡´Â ¼Òµ¶ ĸ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀÔ´Ï´Ù. °Ô´Ù°¡ °¨¿° °ü¸®¿¡ ÁßÁ¡À» µÎ°í ÀÎÁöµµ¸¦ ³ôÀ̰í Á¦Ç° Ãâ½Ã¸¦ °ÈÇÏ¸é ¼Òµ¶ ĸ ½ÃÀåÀ» ´õ¿í °ÈÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
HAIÀÇ ¸¸¿¬Àº ¼Òµ¶ ĸ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀÔ´Ï´Ù. WHO¿¡ µû¸£¸é ±Þ¼º±â º´¿ø ȯÀÚ 100¸í Áß °í¼Òµæ ±¹°¡¿¡¼´Â 7¸í, ÁßÀú¼Òµæ ±¹°¡¿¡¼´Â 15¸íÀÌ ÀÔ¿ø Áß Àû¾îµµ 1ȸ ÀÇ·á °ü·Ã °¨¿°(HAI)À» ¹ßº´Çϰí ÀÖ½À´Ï´Ù. WHO¿¡ µû¸£¸é À̵é ȯÀÚ Áß Æò±Õ 10¸í Áß 1¸íÀÌ HAI·Î ÀÎÇØ »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ CDCÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹ÀÇ ¸ÞƼ½Ç¸° ³»¼º ½ºÅ¸ÇÊ·ÎÄÚÄ¿½º ¾Æ¿ì·¹¿ì½º(MRSA) À¯º´·üÀº 2020³â¿¡¼ 2021³â¿¡ °ÉÃÄ 14% Áõ°¡ÇßÀ¸¸ç ÀΰøÈ£Èí±â °ü·Ã »ç°Ç(VAE)Àº 2021³â 12% Áõ°¡Çß½À´Ï´Ù.
¼Òµ¶ ĸ ½ÃÀåÀº Á¡Àû Á¢¼ÓºÎÀÇ ¼¼Á¤¿¡ »ç¿ëµÇ±â ¶§¹®¿¡ ¾ÏÀÇ ÀÌȯÀ²ÀÌ »ó½ÂÇϰí ÀÖ´Â °ÍÀÌ Å« ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, WHO¿¡ µû¸£¸é ¾ÏÀº 2020³â¿¡ ¼¼°è¿¡¼ 1,000¸¸¸í ÀÌ»óÀÌ »ç¸ÁÇÏ´Â ÁÖ¿ä »çÀÎÀÔ´Ï´Ù. ¶Ç, WCRF¿¡ ÀÇÇϸé, 2020³â¿¡´Â ¼¼°è¿¡¼ ¾à 1,800¸¸¸íÀÇ ¾Ï ȯÀÚ°¡ »õ·Ó°Ô ¹ß»ýÇÑ´Ù°í Çϰí ÀÖ½À´Ï´Ù. ¾Ï ȯÀÚ´Â ¸é¿ª·ÂÀÌ ÀúÇϵǰí ÀÖÀ» °¡´É¼ºÀÌ Àֱ⠶§¹®¿¡ ¾Ï Ä¡·áÁß¿¡ ÀûÀýÇÑ °¨¿° °ü¸®¸¦ ½Ç½ÃÇØ, °¨¿°ÁõÀÇ ¸®½ºÅ©¸¦ ÃÖ¼ÒÇÑÀ¸·Î ¾ïÁ¦ÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. °¨¿°Àº Ä¡·á¿Í ȸº¹ °úÁ¤À» ´õ¿í º¹ÀâÇÏ°Ô Çϱ⠶§¹®¿¡ ¼Òµ¶ ĸÀº ¾Ï ȯÀÚ¿¡°Ô ÇÊ¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù.
°Ç° °ü¸® ÁöÃâ Áõ°¡´Â °í±Þ ÀÇ·á±â±â ¹× °¨¿° Á¦¾î Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ¼Òµ¶ ĸ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î WHO º¸°í¼¿¡ µû¸£¸é Á¤ºÎ ÁöÃâ°ú ¿ÜºÎ ¿øÁ¶ Áõ°¡·Î ÀÎÇØ ¼¼°è ÀÇ·á ÁöÃâÀº 2020³â 9Á¶ ´Þ·¯¸¦ ³Ñ¾î¼¹½À´Ï´Ù. WHO º¸°í¼¿¡ µû¸£¸é WHO ȸ¿ø 50°³±¹ Áß 3ºÐÀÇ 2 À̻󿡼 º¸°Ç½Ã½ºÅÛÀÇ °Å¹ö³Í½º¿Í °ü¸®¿¡ ´ëÇÑ ÁöÃâÀÌ Æò±Õ 7% Áõ°¡Çß½À´Ï´Ù. °Ç° °ü¸® Á¦°ø¾÷ü´Â ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÏ°í °¨¿°°ú °ü·ÃµÈ Àü¹ÝÀûÀÎ ºñ¿ë ºÎ´ãÀ» ÁÙÀÌ´Â Á¦Ç°¿¡ ÅõÀÚÇϱ⠶§¹®¿¡ ¼Òµ¶ ĸ ½ÃÀåÀº ÀÌ·¯ÇÑ Ãß¼¼¿¡¼ ÀÌÀÍÀ» ¾ò°í ÀÖ½À´Ï´Ù.
°¨¿° °ü¸® ÀýÂ÷´Â ÀÇ·á ½Ã¼³ ¹× ±ÔÁ¦ ´ç±¹À¸·ÎºÎÅÍ ´õ¿í ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ȯÀÚÀÇ ¾ÈÀü¼ºÀ» ³ôÀ̰í HAI ¹ß»ý ºóµµ¸¦ ³·Ãß±â À§ÇØ ¾ö°ÝÇÑ ±ÔÁ¦¿Í ±âÁØÀÌ µµÀԵǾú½À´Ï´Ù. °¨¿°°ú HAI¸¦ ÁÙÀ̱â À§ÇØ Á¤ºÎ ±â°üÀÌ ´Ù¾çÇÑ ÇÁ·Î±×·¥À» Á¶Á÷Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼Òµ¶ ĸ ½ÃÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ½ÅÈï °¨¿° ÇÁ·Î±×·¥(EIB)Àº CDC°¡ ¹Ì±¹ ³ó¹«ºÎ ¹× ±âŸ 10°³ ¹Ì±¹ ½Ã¼³°ú Çù·ÂÇÏ¿© ½Ç½ÃÇß½À´Ï´Ù. °øÁß º¸°Ç¿¡ Áß¿äÇÑ Ä§½À¼º ¹ÚÅ׸®¾Æ °¨¿°À» ¸ð´ÏÅ͸µÇϱâ À§ÇØ ABCs¶ó°í ºÒ¸®´Â ½ÇÇè½Ç°ú Áý´Ü ±â¹ÝÀÇ È°¹ßÇÑ °¨½Ã ½Ã½ºÅÛÀÌ »ç¿ëµÇ°í ÀÖÀ¸¸ç EIB¿¡¼ »ç¿ëµË´Ï´Ù. IPC(infection prevention and control)´Â ȯÀÚ¿Í °Ç°°ü¸®ÀÚ¿¡°Ô ¼Õ»óÀ» ÀÔÈú ¼ö ÀÖ´Â °¨¿°À» ÇÇÇϱâ À§ÇØ WHO°¡ °³¹ßÇÑ Áõ°Å ±â¹Ý Çö½ÇÀûÀÎ Àü·«ÀÔ´Ï´Ù.
¼Òµ¶ ĸ ½ÃÀåÀº ¼ºÀ塤°³Ã´À» ÀÌ·ç°í ÀÖ½À´Ï´Ù¸¸, ½ÃÀå È®´ë¿¡ ¿µÇâÀ» ÁÖ´Â ¾ïÁ¦¿äÀÎÀ̳ª °úÁ¦µµ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼Òµ¶ ĸÀÇ ÀåÁ¡°ú Á߿伺¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ȯÀÚÀÇ Áö½ÄÀÌ Á¦ÇÑµÇ¾î ½ÃÀå È®´ë¸¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÃÀå¿¡´Â ´Ù¾çÇÑ ÀÇ·á±â±â°¡ Á¸ÀçÇϱ⠶§¹®¿¡ ¼Òµ¶ ĸÀÇ º¸ÆíÀûÀΠȣȯ¼ºÀ» À¯ÁöÇϱⰡ ¾î·Á¿ï ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ¹ý±Ô¿¡ ´ëÀÀÇϰí ÇÊ¿äÇÑ ÀÎÁõÀ» ÃëµæÇÏ´Â µ¥´Â ½Ã°£°ú ºñ¿ëÀÌ µé±â ¶§¹®¿¡ ¼Òµ¶½ÃÀåÀÇ ¼ºÀåÀÌ µÐÈµÇ°í ½Å±Ô ÁøÀÔÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù.
ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È ¼Òµ¶ ĸ ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ´Ù¾çÇÑ ¿äÀÎÀ¸·Î´Â HAI Áõ°¡, °·ÂÇÑ °Ç° °ü¸® ½Ã½ºÅÛÀÇ Á¸Àç, °·ÂÇÑ Á¤ºÎ ÇÁ·Î±×·¥, °¨¿°ÀÇ ºÎÁ¤ÀûÀÎ ¿µÇâ¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Sepsis Alliance¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â ¸Å³â 60,000¸í ÀÌ»óÀÇ ÁßÁõ ÆÐÇ÷Áõ ȯÀÚ°¡ ÀÀ±Þ ÀÇ·á ¼ºñ½º¿¡ ÀÇÇØ Ä¡·áµÇ°í ÀÖÀ¸¸ç ½ÉÀå ¸¶ºñ¿Í ³úÁ¹Áß È¯ÀÚÀÇ Çհ躸´Ù ¸¹´Ù°í ¹Ï½À´Ï´Ù. °Ô´Ù°¡ ÀÌ Áö¿ª¿¡´Â 3M, B Braun, ICU Medical µî ¼Òµ¶ ĸÀÇ ÁÖ¿ä Á¦Á¶¾÷ÀÚ¿Í ÆÇ¸ÅÀÚ°¡ Á¸ÀçÇϱ⠶§¹®¿¡ ½ÃÀå È®´ë°¡ ±â´ëµÇ°í ÀÖ½À´Ï´Ù.
3MÀº ¹Ì±¹¿¡ º»»ç¸¦ µÐ ´Ù±¹Àû º¹ÇÕ±â¾÷ÀÔ´Ï´Ù. 3MÀº ȯÀÚ °á°ú, °¨¿° ¿¹¹æ ¹× °Ç° °ü¸® Àü¹ÝÀÇ È¿À²¼º Çâ»óÀ» ¸ñÀûÀ¸·Î ´Ù¾çÇÑ Á¦Ç°, ±â¼ú ¹× ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. 3MTM Curos(TM) Disinfecting Cap for Needleless Connectors¶ó´Â ¾ËÄÚ¿Ã ÇÔÀ¯ ĸÀº Æ÷Æ®¿¡ ºñƲ¾î ÀåÂøµÇ¾î ¼Òµ¶ ¹× ½Çµå¸¦ ¼öÇàÇÕ´Ï´Ù. ICU MedicalÀº ÁÖÀÔ ½Ã½ºÅÛ, Á¤¸Æ Ä«Å×ÅÍ, Ä¡¸íÀûÀÎ ÄÉ¾î ¸ð´ÏÅ͸µ, ´Ïµé¸®½º Ä¿³ØÅÍ µî ´Ù¾çÇÑ Á¦Ç°°ú ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ È¸»ç°¡ °³¹ßÇÑ SwabCap(TM) ¼Òµ¶ ĸÀº ¹«±Õ °³º° Æ÷ÀåÀ¸·Î 30ÃÊ À̳»¿¡ ÃÖ´ë 7ÀÏ µ¿¾È ¼Òµ¶ÇÒ ¼ö ÀÖ½À´Ï´Ù. Omnia Health´Â Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç ¹× ÄÁ¼³ÆÃÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¼ºñ½º ¹× ¼Ö·ç¼ÇÀ» ÀÇ·á Á¾»çÀÚ ¹× °ø±Þ¾÷ü¿¡°Ô Á¦°øÇÕ´Ï´Ù. iVCAPÀº ¸éºÀÀÌ »ç¿ë °¡´ÉÇÑ ·ç¾î ¾×¼¼½º ¹ëºêÀÇ Ä¿¹ö·Î »ç¿ëµÇ¸ç ÀáÀçÀûÀÎ ¿À¿°À¸·ÎºÎÅÍ º¸È£Çϱâ À§ÇØ È¸»ç°¡ ¼³°èÇÑ °ÍÀÔ´Ï´Ù. Becton DickinsonÀº ÀÇ·á ±â°ü, »ý¸í °úÇÐ ¿¬±¸ ¹× ÀÓ»ó °Ë»ç¸¦ Æ÷ÇÔÇÑ °Ç° °ü¸® »ê¾÷ÀÇ ´Ù¾çÇÑ ºÐ¾ß¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ½À´Ï´Ù. BD PureHub(TM) ¼Òµ¶ ĸÀº ¶óÀÎ ¾×¼¼½º »çÀÌÀÇ ¹°¸®Àû À庮 ¿ªÇÒÀ» ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¾×¼¼½º Àü¿¡ ½º¿Ò °¡´ÉÇÑ ¹Ù´ÃÀÌ ¾ø´Â ·ç¾î ¿¬°áºÎ¸¦ ¼¼Ã´ÇÏ´Â µµ±¸·Îµµ »ç¿ëµË´Ï´Ù.
2019³â 11¿ù, Asset MedicalÀº ÃֽŠÁ¦Ç°ÀÎ SwabArt(R) ¼Òµ¶ ĸÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ´Â 70% IPA·Î Æ÷ÈµÈ °íÈí¾×¼º ½ºÆùÁö·Î °¨¿°À¸·ÎºÎÅÍ º¸È£ÇÏ´Â ´ÜÀÏ »ç¿ë ¼Òµ¶ Á¦Ç°ÀÔ´Ï´Ù. 2019³â 11¿ù, ICU MedicalÀº ¹«Ä§ Á¡Àû Ä¿³ØÅÍ ¹× ±âŸ °¨¿° Á¦¾î ±â¼úÀ» È®´ëÇϱâ À§ÇØ Pursuit Vascular, Inc¸¦ 7,500¸¸ ´Þ·¯¿¡ ÀμöÇÒ °ÍÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù. Pursuit VascularÀÇ ÁÖ¿ä Á¦Ç°Àº Ç÷¾× Åõ¼® Ä«Å×ÅÍÀÇ À¯Áö º¸¼ö¿¡ »ç¿ëµÇ´Â ClearGuard¢ç HD ĸÀ̾ú½À´Ï´Ù.
The disinfection cap market is estimated to grow at a CAGR of 8.03% during the forecast period.
Disinfectant caps serve as an extra layer of defense against microbial contamination to lower the incidence of illnesses linked to medical equipment. The growing prevalence of healthcare-acquired infections and cancer cases are major growth drivers in the disinfection cap market. Moreover, the increasing emphasis on infection control and rising awareness coupled with enhanced product launches are further expected to bolster the disinfection cap market.
The growing prevalence of HAIs is a major growth driver of the disinfection cap market. According to the WHO, seven patients in high-income countries and 15 patients in low- and middle-income countries out of every 100 patients in acute-care hospitals acquire at least one healthcare-associated infection (HAI) during their hospital stay. On average, one in ten of these patients is expected to die from their HAI as per the WHO. Moreover, the methicillin-resistant Staphylococcus aureus (MRSA) prevalence rate in the USA increased by 14% in 2021 from 2020 and ventilator-associated events (VAE) increased by 12% in 2021 as per the CDC data.
The disinfection cap market is being driven in large part by the rising incidence of cancer as these are used to clean IV connections. For instance, cancer is the leading death cause with more than 10 million worldwide deaths in 2020 according to the WHO. There were around 18 million new cancer cases worldwide in 2020 as per the WCRF. It is important to maintain proper infection control practices during cancer treatment to minimize the risk of infections, as cancer patients may have compromised immune systems. Infections can further complicate the treatment and recovery process therefore disinfection cap is a necessary component for cancer patients.
Increasing healthcare expenditure is driving the demand for advanced medical devices and infection control products thereby propelling the disinfection cap market. For instance, global health spending topped $9 trillion in 2020 owing to increased government spending and external aid as per the WHO report. In more than two-thirds of the 50 WHO nations, spending on health system governance and administration increased by an average of 7%. The disinfection cap market benefits from this trend as healthcare providers invest in products that improve patient outcomes and reduce the overall cost burden associated with infections.
Infection control procedures are receiving more attention from healthcare facilities and regulatory agencies. To enhance patient safety and lower the frequency of HAIs, strict restrictions and standards are being introduced. Various programs are being organized by the government institution to reduce infections and HAIs which is aiding the disinfection cap market. For instance, the Emerging Infections Program (EIB) is being run by CDC in collaboration with the US Department of Agriculture, and 10 other US sites. An active laboratory- and population-based surveillance system called ABCs is used to monitor invasive bacterial infections that are significant for public health and is used by EIB. IPC (infection prevention and control) is a realistic, evidence-based strategy developed by the WHO for avoiding infections that might damage patients and healthcare professionals.
The disinfection cap market has experienced growth and development, however, some restraints or challenges can impact its expansion. For example, healthcare professionals and patients' limited knowledge of the advantages and significance of disinfection caps may restrain market expansion. Moreover, due to the variety of medical equipment in the market, maintaining universal compatibility of disinfection caps might be difficult. Additionally, meeting regulatory compliance and obtaining necessary certifications can be time-consuming and expensive, potentially slowing down the disinfection market growth and limiting the entry of new players.
The North American region is anticipated to hold a significant share of the disinfection cap market during the forecasted period. Various factors propelling the market growth in the region are higher HAIs, the presence of a strong healthcare system, robust government programs, and increased awareness about the adverse effects of infection. For instance, over 60,000 more severe sepsis patients are thought to be treated by emergency medical services in the United States each year than heart attack and stroke patients combined as per the Sepsis Alliance. Moreover, the presence of major producers and distributors of disinfection caps in the region such as 3M, B Braun, and ICU Medical is further expected to aid the market expansion.